Skip to Content
Merck
CN

Y0000364

Clioquinol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

5-Chloro-7-iodo-8-quinolinol, 5-Chloro-8-hydroxy-7-iodoquinoline, Clioquinol, Iodochlorhydroxyquin

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C9H5ClINO
CAS Number:
130-26-7
Molecular Weight:
305.50
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329830920
MDL number:
MFCD00006787
Beilstein/REAXYS Number:
153637

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Clioquinol, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H

SMILES string

Oc1c(I)cc(Cl)c2cccnc12

InChI key

QCDFBFJGMNKBDO-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

clioquinol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Clioquinol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

J Tateishi
Neuropathology : official journal of the Japanese Society of Neuropathology, 20 Suppl, S20-S24 (2000-10-19)
It remains a tragic event that some 10,000 individuals in Japan developed a unique neurologic disease, subacute myelo-optico-neuropathy (SMON). Many of the affected patients still suffer serious sequelae, such as dysesthesia and muscle weakness in the lower extremities, and loss
Jie Geng et al.
Advanced healthcare materials, 1(3), 332-336 (2012-11-28)
Metal ions play important roles in amyloid aggregation and neurotoxicity. Metal-ion chelation therapy has been used in clinical trials for Alzheimer's disease (AD) treatment. However, clinical trial studies have shown that long-term use of metal chelator can cause adverse side
Simon Melov
Trends in neurosciences, 25(3), 121-123 (2002-02-20)
Alzheimer's disease (AD) is a devastating age-related neurodegenerative disorder that has been intensively studied over the last several years. In vitro and in vivo studies have led to an understanding of some of the physico-chemical properties of amyloid, a well-characterized
Lin W Hung et al.
Future medicinal chemistry, 4(8), 955-969 (2012-06-02)
In 1906, Alois Alzheimer first characterized the disease that bears his name. Despite intensive research, which has led to a better understanding of the pathology, there is no effective treatment for this disease. Of the drugs approved by the US
T W Meade
British journal of preventive & social medicine, 29(3), 157-169 (1975-09-01)
Between about 1955 and 1970, some 100,000 Japanese were diagnosed as having subacute myelooptic neuropathy (SMON), a new disease characterized by abdominal and neurological manifestations, the former nearly always preceding the latter. Circumstantial evidence obtained in 1969-70 suggested that SMON
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service